BRISBANE, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (CDNA, Financial), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announced today that it is set to join the Russell 2000, Russell 3000 and Russell Microcap Indexes at the conclusion of the Russell US Indexes annual reconstitution, effective after the US market opens on June 25, 2018.
“Inclusion in the Russell Indexes validates the tremendous strides the company is making with transplant patients, in the market place and in the investment community,” said Peter Maag, CareDx President and Chief Executive Officer. “We look forward to the increased visibility inclusion in these indexes provides CareDx.”
Membership in the Russell 2000, Russell 3000 and Russell Microcap Indexes, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its US Indexes primarily by objective, market-capitalization rankings and style attributes.
Russell US Indexes are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell US Indexes. Russell US Indexes are part of FTSE Russell, a leading global index provider.
About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products along the pre- and post-transplant testing continuum.
For more information, please visit: www.CareDx.com.
CONTACT:
Investor Relations
David Clair
Integrated Corporate Relations, Inc.
+1 646-277-1266
[email protected]
